Supportive Care in Cancer

, Volume 27, Issue 5, pp 1945–1949 | Cite as

Efficacy and safety of Viscum album extract (Helixor-M) to treat malignant pleural effusion in patients with lung cancer

  • Yun-Gyoo Lee
  • Ina Jung
  • Dong-Hoe Koo
  • Du-Young Kang
  • Tae Yoon Oh
  • Sukjoong Oh
  • Seung-Sei LeeEmail author
Original Article



Manifestations of malignant pleural effusions (MPEs) are alleviated by local therapies as well as by systemic treatment. After 2009, when commercial use of talc was discontinued in Korea, we have used Helixor-M, which is derived from the European mistletoe (Viscum album), as an alternative sclerosing agent for pleurodesis. We aimed to evaluate the efficacy and safety of Helixor-M for controlling MPE.


Between 2009 and 2015, we consecutively enrolled 52 patients with lung cancer, who underwent pleurodesis to treat MPE and were analyzed retrospectively. On day 1, 100 mg of Helixor-M was instilled via pleural catheter. If the procedure was not effective, it was repeated every other day up to five times, and the dose increased each time by 100 mg. The primary study outcome was reappearance of pleural effusion at 1 month after the last pleurodesis procedure.


The median age of patient was 63 years, and 77% of the 52 patients were male. About 85% of pleural effusions were found to be malignant by cytogenetic analysis. Forty-two (81%) patients were evaluable for recurrence of MPE. The 1-month recurrence rate was 48% (20/42). Among the 20 patients who developed recurrent MPE, 6 required therapeutic thoracentesis. Thirteen (25%) patients experienced procedure-related pain requiring medication. Eight (15%) had fever > 38 °C.


Our results suggest that a pleurodesis with Helixor-M was an effective and tolerable procedure for controlling MPE in lung cancer patients.


Malignant pleural effusion Pleurodesis Viscum album 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of Kangbuk Samsung Hospital Institutional Review Board (No. KBSMC 2016–07-045) and with the 1964 Declaration of Helsinki and its later amendments.


  1. 1.
    Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ, Group BTSPDG (2010) Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax 65(Suppl 2):ii32–ii40CrossRefPubMedGoogle Scholar
  2. 2.
    Xia H, Wang XJ, Zhou Q, Shi HZ, Tong ZH (2014) Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-analysis. PLoS One 9:e87060CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Campos JR, Werebe EC, Vargas FS, Jatene FB, Light RW (1997) Respiratory failure due to insufflated talc. Lancet 349:251–252CrossRefPubMedGoogle Scholar
  4. 4.
    Rehse DH, Aye RW, Florence MG (1999) Respiratory failure following talc pleurodesis. Am J Surg 177:437–440CrossRefPubMedGoogle Scholar
  5. 5.
    de Campos JR, Vargas FS, de Campos Werebe E, Cardoso P, Teixeira LR, Jatene FB, Light RW (2001) Thoracoscopy talc poudrage : a 15-year experience. Chest 119:801–806CrossRefPubMedGoogle Scholar
  6. 6.
    Mueller EA, Anderer FA (1990) A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer. Cancer Immunol Immunother 32:221–227CrossRefPubMedGoogle Scholar
  7. 7.
    Bussing A, Regnery A, Schweizer K (1995) Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett 94:199–205CrossRefPubMedGoogle Scholar
  8. 8.
    Evans M, Bryant S, Huntley AL, Feder G (2016) Cancer Patients' experiences of using mistletoe (Viscum album): a qualitative systematic review and synthesis. J Altern Complement Med 22:134–144CrossRefPubMedGoogle Scholar
  9. 9.
    Stumpf C, Bussing A (1997) Stimulation of antitumour immunity by intrapleural instillation of a Viscum album L. extract. AntiCancer Drugs 8(Suppl 1):S23–S26CrossRefPubMedGoogle Scholar
  10. 10.
    Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr (1972) Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 77:507–513CrossRefGoogle Scholar
  11. 11.
    Kim JJ, Lee SK, Choi HH (2004) Viscum album therapy in malignant pleural effusion. Korean J Thorac Cardiovasc Surg 37:978–982Google Scholar
  12. 12.
    Cardillo G, Facciolo F, Carbone L, Regal M, Corzani F, Ricci A, Di Martino M, Martelli M (2002) Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions. Eur J Cardiothorac Surg 21:302–305 discussion 305-306CrossRefPubMedGoogle Scholar
  13. 13.
    Steger V, Mika U, Toomes H, Walker T, Engel C, Kyriss T, Ziemer G, Friedel G (2007) Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses. Ann Thorac Surg 83:1940–1945CrossRefPubMedGoogle Scholar
  14. 14.
    Yildirim H, Metintas M, Ak G, Metintas S, Erginel S (2008) Predictors of talc pleurodesis outcome in patients with malignant pleural effusions. Lung Cancer 62:139–144CrossRefPubMedGoogle Scholar
  15. 15.
    Shaw P, Agarwal R (2004) Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev.
  16. 16.
    Janssen JP, Collier G, Astoul P, Tassi GF, Noppen M, Rodriguez-Panadero F, Loddenkemper R, Herth FJ, Gasparini S, Marquette CH, Becke B, Froudarakis ME, Driesen P, Bolliger CT, Tschopp JM (2007) Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 369:1535–1539CrossRefPubMedGoogle Scholar
  17. 17.
    Martinez-Moragon E, Aparicio J, Rogado MC, Sanchis J, Sanchis F, Gil-Suay V (1997) Pleurodesis in malignant pleural effusions: a randomized study of tetracycline versus bleomycin. Eur Respir J 10:2380–2383CrossRefPubMedGoogle Scholar
  18. 18.
    Davies HE, Lee YC (2013) Management of malignant pleural effusions: questions that need answers. Curr Opin Pulm Med 19:374–379CrossRefPubMedGoogle Scholar
  19. 19.
    de Giorgio A, Stebbing J (2013) Mistletoe: for cancer or just for Christmas? Lancet Oncol 14:1264–1265CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Yun-Gyoo Lee
    • 1
  • Ina Jung
    • 1
  • Dong-Hoe Koo
    • 1
  • Du-Young Kang
    • 2
  • Tae Yoon Oh
    • 2
  • Sukjoong Oh
    • 1
  • Seung-Sei Lee
    • 1
    Email author
  1. 1.Department of Internal Medicine, Kangbuk Samsung HospitalSungkyunkwan University School of MedicineSeoulRepublic of Korea
  2. 2.Department of Cardiovascular and Thoracic Surgery, Kangbuk Samsung HospitalSungkyunkwan University School of MedicineSeoulRepublic of Korea

Personalised recommendations